The program started in 1974 as a pilot screening for phenylketonuria (PKU) and was gradually expanded with measurement of the activity of the enzyme of glucose 6-phosphate dehydrogenase (G6PD) and the control of congenital hypothyroidism (CH) and galactosemia (TGAL). This evidence concerns the gene G6PD and galactosemia.